RxDoctor Payments Data

Paul Obrien, MD

Cardiovascular Disease · Annandale, VANPI 1992865588

Payments from drug & device makers

$7,434in general payments, 2019–2025

Across 385 payments — averaging $19.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • Boehringer Ingelheim$980
  • Amgen$828
  • Pfizer$591
  • Johnson & Johnson$560
  • AstraZeneca$507
  • plus $3K from 30 others

What the payments were for

  • Food & beverage$7,434100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,434 in reported general payments places this provider in the 75th percentile of 548 cardiovascular disease providers in Virginia.

See all cardiovascular disease providers in Virginia

Medicare billing

Part B allowed, 2024
$346,726
Medicare patients
660
Services billed
2,825

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban209$307,121
EntrestoSacubitril/Valsartan138$193,246
Repatha SureclickEvolocumab141$126,281
JardianceEmpagliflozin81$89,049
FarxigaDapagliflozin Propanediol39$54,460
XareltoRivaroxaban35$46,037
Eplerenone141$11,307
Praluent PenAlirocumab11$8,924
VascepaIcosapent Ethyl13$8,382
Dabigatran EtexilateDabigatran Etexilate Mesylate31$8,364
Ezetimibe265$8,356
Metoprolol Succinate402$7,634
Atorvastatin Calcium599$7,005
Nebivolol Hcl106$5,527
Rosuvastatin Calcium306$5,344

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$591$307,121209 claims
NovartisEntresto$1,010$193,246138 claims
Boehringer IngelheimJardiance$980$89,04981 claims
AstraZenecaFarxiga$507$54,46039 claims
Johnson & JohnsonXarelto$560$46,03735 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 548 cardiovascular disease providers in Virginia.

Other cardiovascular disease in Annandale

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →